Idenix Pharmaceuticals, Inc.

Universitá Degli Studi Di Cagliari

Other

Centre National De La Recherche Scientifique

Universitè De Montpellier

Centre National De La Recherche Scientifique-cnrs

L'université Montpellier Ii

Paolo La Colla

Jean-Pierre Sommadossi

Marino Artico

Martin L Bryant

Richard Storer

Vadim Bichko

Gilles Gosselin

David N Standring

Lin Qu

A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1', 2&#x2032; or 3&#x2032;-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Methods and compositions for treating hepatitis C virus

The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2'-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

2'-branched nucleosides and flaviviridae mutation

The invention concerns novel substituted 6-benzyl-4-oxopyrimidines and pharmaceutically acceptable salts thereof. These compounds inhibit reverse transcriptase encoded by human immunodeficiency virus (HIV), and are useful to prevent and treat HIV infection and acquired immune deficiency syndrome (AIDS). Pharmaceutical compositions containing the compounds and a method of use of the present compounds and other agents for the treatment of AIDS and viral infection by HIV are also envisaged.

Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them

A method for inhibiting sexual transmission of HIV comprising topically applying to the skin or epithelial tissue of a human a composition comprising a non-nucleoside reverse transcriptase inhibitor (&ldquo;NNRTI&rdquo;) that is able to inhibit viral replication for periods exceeding 12, 24, or even 36 days, at concentrations below even 10 &mgr;M. In one embodiment the NNRTI is a dihydro-alkyloxy-benzyl-oxopyrimidine (DABO).

Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines

Growing community of inventors

Sardinia, Italy

Paolo La Colla